Clinical trial
Safety And Efficacy Of Xalatan Delivered Using Either A Conventional Dropper…
NCT00283764 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Withdrawn
Key facts
| NCT number | NCT00283764 |
|---|---|
| Title | Safety And Efficacy Of Xalatan Delivered Using Either A Conventional Dropper Bottle or A Delivery Device |
| Official title | A Phase 3, 12-Week, Parallel-Design Study Comparing The Safety, Efficacy, and Ease Of Use Of Xalatan When Self-Administered By Subjects With Open-Angle Glaucoma Or Ocular Hypertension Using Either A Conventional Dropper Bottle Or A Forced-Flow Delivery Device |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Withdrawn |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Glaucoma, Open-Angle, Ocular Hypertension |
| Intervention type | Drug |
| Interventions | Xalatan |
| Enrollment | 0 |
| First posted | Jan 30, 2006 |
| Last update posted | Feb 2, 2021 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: